View Filing Data

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2015	Mar. 17, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 39.9
Trading Symbol	OPGN
Entity Common Stock, Shares Outstanding		12,574,303

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 7,814,220	$ 749,517
Accounts receivable, net	678,646	503,983
Inventory, net	826,012	369,742
Prepaid expenses and other current assets	572,489	90,233
Total current assets	9,891,367	1,713,475
Property and equipment, net	1,074,710	587,956
Deferred IPO issuance costs	0	296,041
Intangible assets, net	1,888,814	0
Goodwill	637,528	0
Other noncurrent assets	270,327	57,459
Total assets	13,762,746	2,654,931
Current liabilities
Accounts payable	2,285,792	1,160,081
Accrued compensation and benefits	1,081,270	423,099
Deferred rent, current portion	303,719	26,000
Accrued liabilities	920,286	967,657
Deferred revenue	50,925	339,171
Short-term notes payable	0	1,505,000
Current maturities of long-term capital lease obligations	251,800	100,499
Short term convertible notes, net of discounts	0	1,500,000
Total current liabilities	4,893,792	6,021,507
Long-term capital lease obligations and other liabilities	377,908	134,149
Notes payable	1,000,000	0
Total liabilities	6,271,700	6,155,656
Commitments and contingencies (Note 10)
Redeemable convertible preferred stock
Total redeemable convertible preferred stock	0	4,564,899
Stockholders' equity (deficit)
Common stock, $.01 par value; 200,000,000 shares authorized; 12,547,684 and 493,178 shares issued and outstanding at December 31, 2015 and 2014, respectively	125,477	4,932
Additional paid-in capital	121,490,994	88,701,737
Accumulated other comprehensive loss	(1,059)	0
Accumulated deficit	(114,124,366)	(96,772,293)
Total stockholders' equity (deficit)	7,491,046	(8,065,624)
Total liabilities, preferred stock and stockholders’ equity (deficit)	13,762,746	2,654,931
Series A Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock
Total redeemable convertible preferred stock	$ 0	$ 4,564,899

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	12,547,684	493,178
Common stock, shares outstanding	12,547,684	493,178
Series A Redeemable Convertible Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0	$ 0.01
Preferred stock, shares authorized	0	6,000,000
Preferred stock, shares issued	0	3,999,864
Preferred stock, shares outstanding	0	3,999,864
Preferred stock, liquidation preference	$ 0	$ 7,999,728

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenue
Product sales	$ 2,701,142	$ 1,236,349
Laboratory services	120,476	478,909
Collaborations revenue	336,102	2,411,120
Total revenue	3,157,720	4,126,378
Operating expenses
Costs of products sold	1,179,771	425,541
Costs of services	367,802	526,196
Research and development	6,002,941	4,368,302
General and administrative	5,834,642	2,312,935
Sales and marketing	4,305,444	2,058,085
Transaction expenses	526,283	0
Total operating expenses	18,216,883	9,691,059
Operating loss	(15,059,163)	(5,564,681)
Other income (expense)
Interest and other income	26,657	156
Interest expense	(1,801,320)	(111,345)
Change in fair value of derivative financial instruments and other	(647,342)	4,400
Total other income (expense)	(2,422,005)	(106,789)
Loss before income taxes	(17,481,168)	(5,671,470)
Income tax benefit	(129,095)	0
Net loss	(17,352,073)	(5,671,470)
Accretion of Series A preferred stock	(243,762)	(627,133)
Net loss available to common stockholders	$ (17,595,835)	$ (6,298,603)
Net loss per common share - basic and diluted (in dollars per share)	$ (2.20)	$ (16.25)
Weighted average shares outstanding - basic and diluted (in shares)	7,980,995	387,590
Net loss	$ (17,352,073)	$ (5,671,470)
Other comprehensive loss - foreign currency translation	(1,059)	0
Comprehensive loss	$ (17,353,132)	$ (5,671,470)

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2013	$ (1,831,441)	$ 3,625	$ 89,265,757	$ 0	$ (91,100,823)
Balance (in shares) at Dec. 31, 2013		362,537
Stock option exercises	$ 8	$ 0	8	0	0
Stock option exercises (in shares)	1	1
Restricted stock unit exercises	$ 0	$ 1,307	(1,307)	0	0
Restricted stock unit exercises (in shares)		130,640
Common shares issued in business combination	0
Stock compensation expense	64,412	$ 0	64,412	0	0
Accretion of Series A preferred stock	(627,133)	0	(627,133)	0	0
Net loss	(5,671,470)	0	0	0	(5,671,470)
Balance at Dec. 31, 2014	(8,065,624)	$ 4,932	88,701,737	0	(96,772,293)
Balance (in shares) at Dec. 31, 2014		493,178
Stock option exercises	$ 2,303	$ 114	2,189	0	0
Stock option exercises (in shares)	11,472	11,472
Beneficial conversion feature	$ 1,427,667	$ 0	1,427,667	0	0
Reclassification of warrant liability to equity	719,675	0	719,675	0	0
Conversion of preferred stock into common shares	7,804,172	$ 73,749	7,730,423	0	0
Conversion of preferred stock into common shares (in shares)		7,374,852
Demand notes tendered for IPO Units	2,100,000	$ 3,500	2,096,500	0	0
Demand notes tendered for IPO Units (in shares)		350,000
Issuance of IPO units, net of offering costs	12,129,133	$ 25,000	12,104,133	0	0
Issuance of IPO units, net of offering costs (in shares)		2,500,000
Additional IPO issuance costs	(58,566)		(58,566)	0	0
Common shares issued in business combination	2,584,090	$ 6,818	2,577,272	0	0
Common shares issued in business combination (in shares)		681,818
Common shares issued in financing	5,000,002	$ 11,364	4,988,638	0	0
Common shares issued in financing (in shares)		1,136,364
Stock compensation expense	1,445,088	$ 0	1,445,088	0	0
Accretion of Series A preferred stock	(243,762)	0	(243,762)	0	0
Foreign currency translation	(1,059)	0	0	(1,059)	0
Net loss	(17,352,073)	0	0	0	(17,352,073)
Balance at Dec. 31, 2015	$ 7,491,046	$ 125,477	$ 121,490,994	$ (1,059)	$ (114,124,366)
Balance (in shares) at Dec. 31, 2015		12,547,684

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (17,352,073)	$ (5,671,470)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	624,653	573,918
Non-cash interest expense including beneficial conversion	1,598,312	84,168
Bad debt expense	0	4,000
Recovery of bad debt	0	(8,400)
Deferred tax benefit	(129,095)	0
Stock compensation expense	1,445,088	64,412
Inventory obsolescence expense	0	21,877
Change in fair value of derivative financial instruments	647,342	0
Other non-cash items	24,010	14,681
Changes in operating assets and liabilities:
Accounts receivable	359,298	(257,686)
Inventory	424,505	(215,906)
Other assets	(319,305)	76,554
Accounts payable	196,444	198,177
Accrued compensation and other liabilities	(1,508,937)	(99,310)
Deferred revenue	(288,246)	(170,557)
Net cash used in operating activities	(14,278,004)	(5,385,542)
Cash flows from investing activities
Cash acquired in business combination	1,367,211	0
Purchases of property and equipment	(185,296)	(39,537)
Net cash provided by (used in) investing activities	1,181,915	(39,537)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs	0	1,937,902
Proceeds from issuance of common stock, net of issuance costs	17,366,620	0
Proceeds from issuance of convertible notes, net of issuance costs	1,388,815	1,472,386
Proceeds from issuance of promissory notes, net of issuance costs	1,741,667	1,488,229
Proceeds from exercise of stock options and warrants	2,293	8
Payments on debt	(155,000)	(5,000)
Payments on capital lease obligations	(175,317)	(105,881)
Deferred IPO issuance costs	0	(13,393)
Net cash provided by financing activities	20,169,078	4,774,251
Effects of exchange rates on cash	(8,286)	0
Net increase (decrease) in cash and cash equivalents	7,072,989	(650,828)
Cash and cash equivalents at beginning of year	749,517	1,400,345
Cash and cash equivalents at end of year	7,814,220	749,517
Supplemental disclosure of cash flow information
Cash paid during the year for interest	194,288	32,296
Supplemental disclosure of noncash investing and financing activities:
Common stock issued for business combination	2,584,090	0
Acquisition of equipment purchased through capital leases and leasehold improvement allowances	580,477	0
Deferred and accrued IPO issuance costs	0	282,648
Convertible Debt [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	300,000	0
IPO [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	2,100,000	0
Series A Preferred Stock [Member]
Supplemental disclosure of noncash investing and financing activities:
Debt Conversion, Converted Instrument, Amount	3,000,000	0
Conversion of Series A preferred stock into common shares	$ 8,183,661	$ 0

Organization

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 – Organization

OpGen, Inc. (“OpGen” of the “Company”) was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the “Merger”) of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, “AdvanDx”) (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp., OpGen’s wholly owned subsidiary formed for the express purpose of effecting the Merger, merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen’s wholly owned subsidiary (see Note 4). OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the “Company.” The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.

OpGen is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. OpGen is developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with more rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The Company’s proprietary DNA tests and bioinformatics address the rising threat of antibiotic resistance by helping physicians and healthcare providers optimize patient care decisions and protect the hospital biome through customized screening and surveillance solutions. The Company’s molecular information solution combines Acuitas® DNA tests, Acuitas Lighthouse™ bioinformatics, CLIA lab services for MDRO surveillance, and a proprietary data warehouse including genomic data matched with antibiotic susceptibility information for microbes and patient information from healthcare providers. The Company is working to deliver our molecular information solution to a global network of customers and partners. The Acuitas DNA tests provide rapid microbial ID, and antibiotic resistance gene information. These products include the QuickFISH® family of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures, the MDRO Gene Test to detect, type, track, and trend antibiotic resistant organisms in real-time and our rapid antibiotic resistance test in development.

The Company’s operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

Going Concern and Management's Plans

12 Months Ended

Dec. 31, 2015

Liquidation Basis Of Accounting Abstract [Abstract]

Going Concern and Management’s Plans

Note 2 - Going Concern and Management’s Plans

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements. The Company raised significant funds in 2015, including:

$0.8 million in short-term notes (in the first quarter of 2015, $0.3 million of demand notes held by an entity controlled by our chief executive officer were settled as partial payment for a 2015 convertible note, and in the second quarter of 2015, $0.2 million of notes from a related party were repaid in cash);

$1.5 million through the issuance of convertible notes;

$12.1 million in net proceeds from its initial public offering (“IPO”) as discussed further below; and

$6.0 million in net proceeds from the issuances of common stock and a senior secured promissory note to Merck Global Health Innovation Fund, LLC (“Merck GHI”).

On May 8, 2015, OpGen completed its IPO pursuant to which it offered and sold 2,850,000 units, each Unit consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was used to satisfy outstanding demand notes by exchanging such notes for 350,000 Units in the IPO. After considering the demand notes, underwriting discounts and commissions and offering expenses, the total net cash proceeds were $12.1 million. On the IPO closing date, the underwriters exercised their over-allotment option to acquire an additional 422,500 stock purchase warrants. In connection with the IPO, all of OpGen’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 1,136,364 shares of common stock at $4.40 per share and a $1.0 million senior secured promissory note to Merck GHI (see Note 5).

The Company’s current operating assumptions, which include management’s best estimate of future revenue and operating expenses, indicate that current cash on hand will be sufficient to fund operations into the second quarter of 2016.

In the event the Company is unable to successfully raise additional capital in 2016, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing, or pursue other strategic alternatives which may include licensing and/or partnering arrangements or mergers and acquisitions. The consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3 - Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting standards in the United States (“U.S. GAAP”). The consolidated financial statements consolidate the operations of all controlled subsidiaries; all intercompany activity is eliminated. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Kroner as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in other comprehensive loss, a component of stockholder's equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2015.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss.

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. Debt is reflective of fair value based on instruments with similar terms available to the Company.

For additional fair value disclosures, see Note 13.

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At December 31, 2015, the Company has funds totaling $243,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other long-term assets on the accompanying consolidated balance sheets.

Accounts Receivable

The Company’s accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $15,596 and $79,697 as of December 31, 2015 and 2014, respectively.

At December 31, 2015, the Company had accounts receivable from one customer which individually represented 25% of total accounts receivable. At December 31, 2014, the Company had accounts receivable from two customers which individually represent 79% and 15% of total accounts receivable. For the year ended December 31, 2015, revenue earned from Hitachi High-Technologies Corporation (“Hitachi”) represented 11% of total revenues. For the year ended December 31, 2014, revenue earned from Hitachi represented 64% of total revenues. This customer contract was completed as of December 31, 2015.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	December 31,
	2015		2014

Raw Materials and supplies	$	362,526	$	40,749
Work-in-process		150,369		135,625
Finished goods		313,117		193,368
Total inventory	$	826,012	$	369,742

Inventory includes the Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $591,051 and $867,816 at December 31, 2015 and 2014, respectively.

Intangible assets and goodwill

Intangible assets as of December 31, 2015 were acquired as part of the Merger, and consist of definite-lived intangible assets and goodwill. Intangible assets acquired in prior years were fully amortized as of December 31, 2014.

Definite-lived intangible assets

Definite-lived intangible assets include trademarks, developed technology and customer relationships, and are amortized over their useful lives of 10, 7 and 7 years, respectively, and consisted of the following as of December 31, 2015:

	Cost		Accumulated Amortization		Net balance at December 31, 2015

Trademarks and tradenames	$	461,000	$	(21,471)	$	439,529
Developed technology		458,000		(30,474)		427,526
Customer relationships		1,094,000		(72,241)		1,021,759
Balance	$	2,013,000	$	(124,186)	$	1,888,814

Total amortization expense of intangible assets was $124,186 and $57,594 for the years ended December 31, 2015 and 2014, respectively. Amortization of intangible assets is expected to be approximately $268,000 per year for the next five years.

Definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During years ended December 31, 2015 and 2014, the Company determined that its definite-lived intangible assets were not impaired.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. As a result of the Merger and subsequent measurement period adjustments (see Note 4), the Company recognized goodwill of $637,528.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. During year ended December 31, 2015, the Company determined that its goodwill was not impaired.

Property and equipment

Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets. The estimated service lives approximate three to five years. Depreciation expense was $500,467 and $516,324 for the years ended December 31, 2015 and 2014, respectively. Property and equipment consisted of the following at December 31, 2015 and 2014:

	December 31,
	2015		2014

Laboratory equipment	$	3,734,044	$	2,304,615
Office furniture and equipment		701,557		691,032
Computers		1,563,177		1,169,910
Leasehold improvements		659,949		245,558
		6,658,727		4,411,115
Less accumulated depreciation		(5,584,017)		(3,823,159)
Property and equipment, net	$	1,074,710	$	587,956

In 2012, the Company began to provide Argus™ Whole Genome Systems under its Argus Reagent Rental Program to customers, in which the Company retains title without requiring customers to purchase the equipment or enter into an equipment lease or rental contract. The costs associated with these instruments are capitalized and charged to sales and marketing on a straight-line basis over the estimated useful life of the instrument, which is approximately four years. During the years ended December 31, 2015 and 2014, sales and marketing expenses related to these costs were approximately $175,000 and $101,000, respectively. The costs to maintain these systems are charged to operations as incurred.

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the years ended December 31, 2015 and 2014, the Company determined that its property and equipment was not impaired.

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Redeemable convertible preferred stock

All shares of Series A redeemable convertible preferred stock (“Series A Preferred Stock”) (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt (see Note 6)), were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Notes 7 and 8).

Prior to the IPO, the carrying value of the Series A Preferred Stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable. At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management’s best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer. Sales are recorded net of accruals for estimated rebates, discounts and other deductions and returns.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company’s funded software development arrangements generally consist of multiple elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, fees paid to consultants and outside service partners.

Share-based compensation

Share-based payments are recognized at fair value. The fair value of share-based payments to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. A discussion of management’s methodology for developing each of the assumptions used in the Black-Scholes model is as follows:

Fair value of common stock

For periods prior to the Company’s IPO, given the lack of an active public market for the common stock, the Company’s board of directors determined the fair value of the common stock. In the absence of a public market, and as an emerging company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The factors include: (1) the achievement of clinical and operational milestones by the Company; (2) the status of strategic relationships with collaborators; (3) the significant risks associated with the Company’s stage of development; (4) capital market conditions for life science and medical diagnostic companies, particularly similarly situated, privately held, early stage companies; (5) the Company’s available cash, financial condition and results of operations; (6) the most recent sales of the Company’s preferred stock; and (7) the preferential rights of the outstanding preferred stock. Since the IPO, the Company uses the quoted market price of its common stock as its fair value.

Expected volatility

Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Until a significant trading history for its common stock develops, the Company has identified several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of this peer group.

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected term of the option to be 6.25 years for options with a standard four-year vesting period, using the simplified method. Over time, management will track actual terms of the options and adjust their estimate accordingly so that estimates will approximate actual behavior for similar options.

Expected forfeiture rate

The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.

The estimated fair value of equity instruments issued to nonemployees are recorded at fair value on the earlier of the performance commitment date or the date the services required are completed.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $90,297,000 and $76,268,000 at December 31, 2015 and 2014, respectively. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) restricted stock units (in 2014), (iii) stock purchase warrants, and (iv) prior to the IPO, convertible preferred stock and convertible debt, exercisable or exchangeable into common stock which have been excluded from the computation of diluted loss per share, was 6.0 million shares and 5.9 million shares for the years ended December 31, 2015 and 2014, respectively. The Company’s convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”), issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for the Company’s reporting year beginning January 1, 2018 and early adoption is permitted starting January 1, 2017. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance 1) provides a definition for the term “substantial doubt,” 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

In September 2015, the FASB issued accounting guidance to simplify the accounting for measurement period adjustments resulting from business combinations. Under the guidance, an acquirer will be required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined. The guidance requires an entity to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date. The Company adopted this new guidance in the fourth quarter of 2015; see Note 4 for the impact of adoption.

In February 2016, the FASB issued accounting guidance which will require most leases (with the exception of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018 but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect of the new standard on its consolidated financial statements and related disclosures.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its financial position, results of operations, or cash flows.

Business Combination

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Business Combination

Note 4 – Business Combination

On July 14, 2015, the Company acquired 100% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced in vitro diagnostic kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to use AdvanDx’s diagnostic capabilities with respect to MDROs and leverage AdvanDx’s relationships with hospitals and clinical laboratories to accelerate the sales of OpGen’s products and services.

Pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate 681,818 shares of the Company’s common stock with a value of $2.6 million (the “Merger Consideration”), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.

The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The fair values are preliminary, are based on the Company’s estimates and may be adjusted from time to time, but no later than July 13, 2016, as better information becomes available. The Company received carryover tax basis in the acquired assets and liabilities and no tax basis in the intangible assets (including goodwill) established on the acquisition date. As a result, the Company recognized deferred tax assets related to foreign taxing jurisdictions of $4.3 million (fully offset by a corresponding valuation allowance) and net deferred tax liabilities of $0.1 million in the U.S taxing jurisdiction. The net deferred tax liability in the U.S. taxing jurisdiction resulted in an income tax benefit related to a reduction in the Company’s previously established valuation allowance (which reduction is accounted for outside of purchase accounting). The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued	$	2,584,090

Fair value of tangible assets acquired:
Cash	$	1,367,211
Receivables		536,406
Inventory		881,273
Property and equipment		245,479
Other assets		359,587
Fair value of identifable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		637,528

Deferred tax liabilities, net		129,095
Fair value of liabilities assumed		3,327,299
	$	2,584,090

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $0.6 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is not tax deductible. The Company expensed acquisition-related costs of approximately $0.5 million related to the Merger in 2015. AdvanDx recognized approximately $1.7 million of revenue and incurred approximately $2.1 million of net losses from the acquisition date to December 31, 2015, which results are included in the Company’s 2015 consolidated financial statements.

Adjustments to Purchase Accounting Estimates

In the fourth quarter of 2015, the Company adopted new accounting guidance with respect to the accounting for measurement period adjustments resulting from business combinations. Under the new guidance, the Company is required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined and disclose the portion of the amount recorded in current-period losses by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date.

In the third quarter of 2015, the Company allocated the total purchase consideration to the assets and liabilities acquired from AdvanDx, based on provisional estimated fair value of those acquired assets and liabilities. During the fourth quarter of 2015, as a result of obtaining new information about facts and circumstances that existed as of the acquisition date, the Company adjusted the provisional estimated fair values, as follows:

	As
	previously				Adjusted
	reported (1)		Adjustment		amount
Accounts receivable	$	557,112	$	(20,706)	$	536,406
Inventory		1,073,855		(192,582)		881,273
Property and equipment		250,636		(5,157)		245,479
Liabilities		3,329,058		(1,759)		3,327,299
Deferred tax liabilities		-		129,095		129,095
Goodwill		291,747		345,781		637,528
Provision (benefit) for income taxes		1,662		(130,757)		(129,095)

(1) As reported on Form 10-Q for the quarter ended September 30, 2015

In the provisional amounts recorded in the third quarter, the Company had anticipated that it would receive “stepped-up” tax bases in the acquired assets and liabilities as a result of making an election under section 338 of the U.S. Internal Revenue Code. In the fourth quarter of 2015, after further tax analysis, the Company decided that it would not make the 338 election and, as such, the Company will receive “carry-over” tax bases in the assets and liabilities acquired. The change in tax treatment resulted in a reduction of the Company’s deferred tax asset valuation allowance in the U.S. taxing jurisdiction that existed prior to the acquisition.

Pro Forma Disclosures (unaudited)

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Merger had been completed as of January 1, 2014. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx’s outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results	Year Ended December 31,
	2015		2014

Revenues	$	5,231,844	$	8,904,244
Net loss	$	(20,751,552)	$	(14,520,497)
Net loss per share	$	(2.52)	$	(6.87)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Merck GHI Financing

12 Months Ended

Dec. 31, 2015

Common Stock and Note Purchase Agreement [Abstract]

Merck GHI Financing

Note 5 – Merck GHI Financing

On July 14, 2015, as a condition to the Merger, the Company entered into a Common Stock and Note Purchase Agreement (the “Purchase Agreement”) with Merck GHI, pursuant to which Merck GHI purchased 1,136,364 shares of common stock of the Company at $4.40 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the “Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company’s obligations under the Note are secured by a lien on all of the Company’s assets.

The Company incurred issuance costs of approximately $50,000 related to the financing, of which approximately $8,000 was deferred as debt issuance costs and are being amortized as interest expense over the life of the Note, and $42,000 was charged to additional paid-in capital.

Redeemable Convertible Preferred Stock

12 Months Ended

Dec. 31, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Redeemable Convertible Preferred Stock

Note 6 - Redeemable Convertible Preferred Stock

All shares of Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt) were converted into 7,374,852 shares of common stock in connection with the Company’s IPO (see Notes 7 and 8). At December 31, 2014, the Company had 3,999,864 shares of Series A Preferred Stock outstanding. The Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company’s redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company’s control.

The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in convertible promissory notes. In February 2014, the Company sold 1,405,096 shares of Series A redeemable convertible preferred stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904. The Company incurred issuance costs of $62,098 related to the 2014 Series A Preferred Stock sales. As of December 31, 2014, the Company had a total of 3,999,864 shares of Series A Preferred Stock outstanding, convertible into 3,999,864 shares of common stock.

The following table presents the changes in the Series A Preferred Stock during 2014 and 2015:

	Shares		Amount
Balance at December 31, 2013		1,999,864	$	1,999,864

February 2014 Issuance		1,405,096		1,361,469
April 2014 Issuance		594,904		576,433
2014 Accretion		-		627,133

Balance at December 31, 2014		3,999,864		4,564,899

2015 Accretion		-		243,762
2015 Conversions		(3,999,864)		(4,808,661)

Balance at December 31, 2015		-	$	-

The Series A Preferred Stock had the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the board of directors. The Series A Preferred Stock had preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences were at two times the Series A Preferred Stock purchase price. The Series A preferred stockholders were entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the common stock. In addition, the Series A Preferred Stock had broad based anti-dilution rights.

The holders of Series A Preferred Stock had the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate was one common share for each preferred share, which may be adjusted for specified dilutive transactions. Beginning in December 2019, the Company may have been obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would have taken place in three equal annual installments. Series A Preferred Stock would have been redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions were subject to certain equity adjustments for specified anti-dilution transactions, as defined.

Debt

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

All the Company’s outstanding demand notes and convertible notes were exchanged for units in the Company’s IPO or otherwise were converted into Series A Preferred Stock and subsequently converted into shares of common stock in connection with the IPO. A short-term 8% promissory note for $150,000 issued in April 2015 was repaid in cash in June 2015. In July 2015, the Company issued a $1.0 million 8% senior secured promissory note to Merck GHI (see Note 5). As of December 31, 2015 and 2014, the Company has a total debt outstanding as follows:

	December 31,
	2015		2014

Convertible notes	$	-	$	1,500,000
Demand promissory notes		-		1,500,000
Long term promissory notes		1,000,000		5,000
	$	1,000,000	$	3,005,000

The long-term promissory notes are due in July 2017 (see Note 5).

In 2009, the Company entered into loan agreements with the Department of Business and Economic Development, a principal department of the State of Maryland, and Montgomery County, Maryland. Under the terms of the agreements, the State of Maryland and Montgomery County loaned the Company $100,000 and $10,000, respectively, to assist in the relocation of the Company’s operations from Wisconsin to Gaithersburg, Maryland. Interest on the loans accrued at 3%. The interest was deferred and the loans were forgivable under certain conditions, including the Company maintaining operations in Gaithersburg, Maryland, and attaining a specified level of staffing at that site on or before December 31, 2012. The Company did not attain the required level of staffing at December 31, 2012, and, as a result, these notes and accrued interest became due in 2013. The Company negotiated a settlement with the State of Maryland under which it paid $75,000 in June 2013 in full satisfaction of the $100,000 loan principal balance and accrued interest of $11,811. The Company also negotiated a settlement with Montgomery County under which accrued interest due under the loan provisions was forgiven and the loan would be paid in equal quarterly installments over the eight quarters ending December 31, 2015. The loan was paid in full during 2015 and no amounts remain outstanding.

Demand notes

In the fourth quarter of 2014 and first quarter of 2015, the Company raised a total of $2.3 million through the issuance of short-term demand notes. In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note. All outstanding demand notes were tendered as payment for 350,000 units in the Company’s IPO (see Note 8). Prior to settlement, the demand notes bore interest at 8% per annum, had a first priority security interest in the assets of the Company, and a term of approximately four months.

2014 convertible debt

In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt. All outstanding 2014 convertible debt was converted into Series A Preferred Stock and then into 1,500,000 shares of common stock in connection with the Company’s IPO (see Note 8). Prior to its conversion, the debt was convertible, at the option of the holders or in certain cases at the Company’s option, into shares of Series A Preferred Stock or other potential equity securities, bore interest at 8% and was due in full on July 11, 2015.

2015 convertible debt

In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. All outstanding 2015 convertible debt was converted into Series A Preferred Stock and then into 1,875,000 shares of common stock in connection with the Company’s IPO (see Note 8). Prior to its conversion, the 2015 convertible notes were prepayable by the Company without penalty at any time following the three-month anniversary of the closing of the IPO (provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO), and were puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes were each convertible, at the election of the holder, into (i) shares of Series A Preferred Stock, at a conversion rate of 1.25 shares of Series A Preferred Stock for each $1.00 converted if the conversion occurs prior to closing of an IPO, or (ii) shares of common stock at a conversion rate of one share of common stock for each $1.00 converted if the conversion occurs after the closing of an IPO.

The conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount) at issuance. After allocation of the gross proceeds to the detachable stock purchase warrants (discussed below) and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes. Upon conversion in May 2015, the remaining unamortized beneficial conversion feature of approximately $1.5 million was charged to interest expense in the accompanying consolidated statement of operations. Remaining unamortized deferred financing costs of $71,421 were also charged to interest expense upon conversion.

The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 225,011 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six-month anniversary of the closing of the IPO. Prior to the IPO, as a result of net settlement features, the stock purchase warrants were considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and were marked-to-market at each balance sheet date through earnings. As a result of the elimination of the net settlement features in the IPO, the stock purchase warrants were marked to fair value of $0.7 million on May 8, 2015 and then reclassified to equity.

Total interest expense on all debt instruments was $1.8 million and $0.1 million in 2015 and 2014, respectively.

Stockholders' Equity

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Deficit

Note 8 - Stockholders’ Equity

As of December 31, 2015, the Company has 200,000,000 shares of authorized common shares and 12,547,684 issued and outstanding, and 10,000,000 of authorized preferred shares, none of which were issued or outstanding.

On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each Unit consisting of one share of common stock and a detachable stock purchase warrant to purchase an additional share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was used to satisfy outstanding demand notes by exchanging such notes for 350,000 Units in the IPO. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $2.9 million (which were charged to additional paid-in capital), the total net cash proceeds to the Company was $12.1 million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire an additional 422,500 stock purchase warrants for cash of $4,225. In connection with the IPO, all of the Company’s outstanding Series A Preferred Stock, 2014 convertible notes and 2015 convertible notes were converted into 7,374,852 shares of common stock.

The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for 3,272,500 shares of common stock at $6.60 per share beginning six months after the closing of the IPO for five years, expiring on May 8, 2020. Additionally, the Company issued additional warrants to its investment bankers to purchase 185,250 shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.

In July 2015, the Company issued 1,136,364 shares of common stock to Merck GHI for cash consideration of $5.0 million (see Note 5).

Stock options

In 2002, the Company adopted the 2002 Stock Option and Restricted Stock Plan (the “2002 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive stock options or non-qualified stock options, shares of restricted stock, shares of unrestricted common stock, and other share-based awards to officers and employees. In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s IPO. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2002 Plan or 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Internal Revenue Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 1,355,000 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of December 31, 2015, 233,562 shares remain available for issuance under the 2015 Plan.

For the years ended December 31, 2015 and 2014, the Company recorded $1.4 million and $0.1 million, respectively, of stock compensation expense. No income tax benefit for stock-based compensation arrangements was recognized in the consolidated statements of operations due to the Company’s net loss position. The allocation of share-based compensation expense by operating expenses is as follows:

	Year Ended December 31,
	2015		2014

Research and development	$	240,739	$	5,234
General and administrative		619,899		55,802
Sales and marketing		584,450		3,376
	$	1,445,088	$	64,412

During 2015 and 2014, the Company granted stock options to acquire 1,961,637 and 401,053 shares of common stock, respectively, at average exercise prices of $2.68 and $0.05 per share and with a weighted average grant date fair values of $2.80 and $0.03, respectively. At December 31, 2015, the Company had unrecognized expense related to its stock options of $3.4 million which will be recognized over a weighted-average period of 1.57 years.

A summary of the status of options granted under the plan is presented below as of and for the years ended December 31, 2015 and 2014:

					Weighted-
			Weighted-		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
	Options		Price		Life (in years)		Value

Outstanding at January 1, 2014		20,956				8.1	$	-
Granted		401,053	$	0.05
Exercised		(1)	$	7.91			$	-
Forfeited		(17,736)	$	40.34
Outstanding at December 31, 2014		404,272	$	1.13		9.3	$	-

Granted		1,961,637	$	2.68
Exercised		(11,472)	$	0.20			$	19,519
Forfeited		(193,657)	$	0.55
Outstanding at December 31, 2015		2,160,780	$	2.60		9.1	$	1,575,646
Exercisable at December 31, 2015		432,340	$	1.36		8.6	$	632,052
Vested and expected to vest		2,138,606	$	2.60		9.1	$	1,555,185

The weighted-average grant-date fair value for the option awards granted during the years ended December 31, 2015 and 2014 was $2.80 and $0.03, respectively. The total fair value of options vested in the years ended December 31, 2015 and 2014, was $1,140,079 and $47,331, respectively. The fair value of each option grant was estimated at the date of grant using the Black -Scholes option pricing model based on the assumptions below:

	Year Ended December 31,
	2015			2014

Annual dividend		-			-
Expected life (in years)		5.5-6.25			6.25
Risk free interest rate		1.46-1.9	%		1.84-2.02	%
Expected volatility		47.7-65.0	%		60.0	%

On October 23, 2014, the Company’s Board of Directors approved grants of stock options to acquire approximately 825,000 shares of common stock under the 2002 Plan, contingent upon obtaining and approving an independent valuation of the fair value of the Company's common stock. These options were approved by the Board of Directors in February 2015, at which time the Company began recognizing stock-based compensation expense.

Restricted stock units

In March 2014, the Company awarded restricted stock units to acquire 130,640 shares of common stock to its Chief Executive Officer (“CEO”). The restricted stock units were compensation for his service as CEO from October 2013 through June 2014 and were subject to forfeiture if he did not continue to perform management services through October 24, 2014. The restricted stock units vested on October 24, 2014 and 130,640 shares of common stock were issued to the CEO. In the fourth quarter of 2015, the Company granted additional restricted stock units to acquire 75,000 shares of common stock, with a weighted average grant date fair value of $1.70 per share, all of which remain outstanding as of December 31, 2015.

Stock purchase warrants

At December 31, 2015 and 2014, the following warrants to purchase shares of common stock were outstanding:

						Outstanding at December 31,
		Exercise
Issuance		Price		Expiration		2015		2014
	August 2007	$	7.91		August 2017		8,921		8,921
	March 2008	$	790.54		March 2018		46		46
	November 2009	$	7.91		November 2019		6,674		6,674
	January 2010	$	7.91		January 2020		6,674		6,674
	March 2010	$	7.91		March 2020		1,277		1,277
	November 2011	$	7.91		November 2021		5,213		5,213
	December 2011	$	7.91		December 2021		664		664
	March 2012	$	109.90		March 2019		4,125		4,125
	February 2015	$	6.60		February 2025		225,011		-
	May 2015	$	6.60		May 2020		3,457,750		-
							3,716,355		33,594

The warrants listed above were issued in connection with various debt, preferred stock or development contract agreements. The warrants issued in February 2015 were initially classified as a liability since the exercise price was variable. The exercise price became fixed as a result of the Company’s IPO and, as such, the warrant liability was marked to fair value at that time and reclassified to equity (see Note 13).

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

Note 9 - Income Taxes

At December 31, 2015 and 2014, the Company had net deferred tax assets of $41,554,045 and $31,505,287, respectively, primarily consisting of NOL carry forwards, research and experimental (“R&E”) credits, and differences between depreciation and amortization recorded for financial statement and tax purposes. The Company’s net deferred tax assets at December 31, 2015 and 2014 have been offset by a valuation allowance of $41,545,045 and $31,505,287, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the deferred tax assets. The Company’s deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows:

	December 31,
	2015		2014
Deferred tax assets:
NOL carryforward	$	38,797,762	$	28,704,237
R&E credit carryforward		1,994,478		1,894,478
Share-based compensation		383,153		144,742
Inventory reserve		226,299		334,578
Depreciation		313,714		246,233
Accruals and other		495,640		185,702
Total deferred tax assets		42,211,046		31,509,970
Valuation allowance		(41,554,045)		(31,505,287)

Deferred tax liabilities:
Intangible assets		(657,001)		-
Fixed assets		-		(4,683)

Net deferred tax liability	$	-	$	-

The difference between the Company’s expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit) relates to the effect of the following:

	2015			2014
Federal income tax benefit at statutory rates		35.0	%		34.0	%
State income tax benefit, net of Federal benefit		3.3	%		3.6	%
Change in valuation allowance		(33.1)	%		(51.1)	%
Change in state tax rates and other		(4.5)	%		13.5	%
		0.7	%		0.0	%

Additionally, despite the NOL carryforwards, the Company may have future tax liability due to alternative minimum tax or state tax requirements. The Company has federal NOL carryforwards of $90,297,225 and $76,267,809 at December 31, 2015 and 2014, respectively. The NOL carry forwards begin to expire in 2022. Utilization of the NOL carryforward may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code. There can be no assurance that the NOL carryforward will ever be fully utilized. To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Internal Revenue Code of 1986, as amended. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Commitments

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments

Note 10 - Commitments

Operating leases

During the second quarter 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. The Company also leases a facility in Woburn, Massachusetts under an operating lease that expires in January 2017, and provides the Company with options to extend the lease beyond the current expiration date. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis. Rent expense under the Company’s facility operating leases for the years ended December 31, 2015 and 2014, was $1,027,174 and $883,155, respectively.

Capital leases

The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2020. The leases require monthly principal and interest payments. Following is a schedule by year of the estimated future minimum payments under all operating and capital leases as of December 31, 2015:

	Capital		Operating
Year ending December 31,	Leases		Leases		Total

2016	$	294,141	$	870,484	$	1,164,625
2017		204,354		633,480		837,834
2018		109,272		568,410		677,682
2019		21,266		-		21,266
2020 and thereafter		19,494		-		19,494
Total	$	648,527	$	2,072,374	$	2,720,901
Less: amount representing interest		(70,255)
Net present value of future minimum lease payments	$	578,272
Current maturities		(251,800)
Long-term maturities	$	326,472

Assets under capital leases were included in the following balance sheet categories as of December 31:

	2015		2014
Laboratory equipment	$	803,500	$	364,471
Office furniture		89,140		-
Computers		153,693		153,693
Less accumulated amortization		(402,066)		(245,030)
Capital lease assets, net	$	644,267	$	273,134

Amortization expense associated with equipment under capital leases for the years ended December 31, 2015 and 2014 was $157,036 and $122,411, respectively, and is included within depreciation and amortization expense in the consolidated statements of operations.

Registration and other shareholder rights

In connection with the Merger and the investment transactions (see Notes 4 and 5), the Company also entered into a Registration Rights Agreement with the AdvanDx stockholders receiving Merger Consideration and with Merck GHI, pursuant to which the investors were granted certain demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company’s common stock. Merck GHI also received rights to participate on a pro-rata basis in future securities offerings by the Company.

On December 18, 2013, the Company entered into the Third Amended and Restated Investors’ Rights Agreement (the “Investors’ Rights Agreement”) with investors acquiring promissory notes convertible into shares of the Company's Series A Preferred Stock. Following the IPO, the holders of 20% or more of such shares of common stock subject to the Investors’ Rights Agreement have demand registration rights and piggyback registration rights in connection with subsequent registered offerings of the Company’s common stock.

License Agreements, Research Collaborations and Development Agreements

12 Months Ended

Dec. 31, 2015

License Agreements Research Collaborations And Development Agreements [Abstract]

License Agreements, Research Collaborations and Development Agreements

Note 11 - License Agreements, Research Collaborations and Development Agreements

The Company is a party to three license agreements to acquire certain patent rights and technologies. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized $205,147 and $97,134 of net royalty expense for the years ended December 31, 2015 and 2014, respectively. In 2016, future minimum royalty fees are $270,000 under these agreements.

In September 2013, the Company entered into a technology development agreement in which the Company would receive fixed milestone payments for meeting development milestones under the agreement. Since the milestones are substantive, the Company recognizes revenue in the periods in which the substantive milestones are achieved. In addition, the Company received an upfront payment of $250,000, which is recognized on a straight-line basis over the term of the technology development agreement. The Company recognized total revenue of $336,102 and $2,411,120 during the years ended December 31, 2015 and 2014, respectively, relating to this arrangement.

Related Party Transactions

12 Months Ended

Dec. 31, 2015

Related party transactions

Note 12 – Related Party Transactions

In March 2014, the Company entered into a supply agreement with Fluidigm Corporation, or Fluidigm, under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company’s CEO and Chairman of the Board of Directors of the Company, is a director of Fluidigm. On July 12, 2015, the Company entered into a letter agreement (the “Fluidigm Agreement”) with Fluidigm to expand the companies’ existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Fluidigm Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company’s existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE-marked diagnostic test for the purpose of detecting resistome genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term is extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms. The Company incurred and paid $370,539 and $138,339 related to these agreements in 2015 and 2014, respectively.

In addition, the Company has several capital lease arrangements for laboratory equipment manufactured by Fluidigm. The Company paid $119,919 and $59,412 related to the leased equipment in 2015 and 2014, respectively.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Fair value measurements

Note 13 – Fair Value Measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1 - defined as observable inputs such as quoted prices in active markets;

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company’s IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company’s equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company’s equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock ) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company’s equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2015:

	Balance at								Balance at
	December		Established		Change in		Reclassified		December
Description	31, 2014		in 2015		Fair Value		to Equity		31, 2015

Derivative warrant liability	$	-	$	72,333	$	647,342	$	(719,675)	$	-

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in 2015 and 2014.

See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Foreign Currency

Foreign Currency

Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of Estimates

Use of Estimates

Fair value of financial instruments

Fair value of financial instruments

For additional fair value disclosures, see Note 13.

Cash and cash equivalents and restricted cash

Cash and cash equivalents and restricted cash

Accounts Receivable

Accounts Receivable

Inventory

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	December 31,
	2015		2014

Raw Materials and supplies	$	362,526	$	40,749
Work-in-process		150,369		135,625
Finished goods		313,117		193,368
Total inventory	$	826,012	$	369,742

Intangible assets and goodwill

Intangible assets and goodwill

Definite-lived intangible assets

	Cost		Accumulated Amortization		Net balance at December 31, 2015

Trademarks and tradenames	$	461,000	$	(21,471)	$	439,529
Developed technology		458,000		(30,474)		427,526
Customer relationships		1,094,000		(72,241)		1,021,759
Balance	$	2,013,000	$	(124,186)	$	1,888,814

Goodwill

Property and equipment

Property and equipment

	December 31,
	2015		2014

Laboratory equipment	$	3,734,044	$	2,304,615
Office furniture and equipment		701,557		691,032
Computers		1,563,177		1,169,910
Leasehold improvements		659,949		245,558
		6,658,727		4,411,115
Less accumulated depreciation		(5,584,017)		(3,823,159)
Property and equipment, net	$	1,074,710	$	587,956

Deferred rent

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Redeemable convertible preferred stock

Redeemable convertible preferred stock

Revenue recognition

Revenue recognition

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of sales.

Revenue from sales of the Argus System

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer. Sales are recorded net of accruals for estimated rebates, discounts and other deductions and returns.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Research and development costs

Research and development costs

Share-based compensation

Share-based compensation

Fair value of common stock

Expected volatility

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

Expected forfeiture rate

The estimated fair value of equity instruments issued to nonemployees are recorded at fair value on the earlier of the performance commitment date or the date the services required are completed.

Income taxes

Income taxes

Loss per share

Loss per share

Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding during the period.

Recent accounting pronouncements

Recent accounting pronouncements

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Schedule of inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	December 31,
	2015		2014

Raw Materials and supplies	$	362,526	$	40,749
Work-in-process		150,369		135,625
Finished goods		313,117		193,368
Total inventory	$	826,012	$	369,742

Schedule of Finite-Lived Intangible Assets

	Cost		Accumulated Amortization		Net balance at December 31, 2015

Trademarks and tradenames	$	461,000	$	(21,471)	$	439,529
Developed technology		458,000		(30,474)		427,526
Customer relationships		1,094,000		(72,241)		1,021,759
Balance	$	2,013,000	$	(124,186)	$	1,888,814

Property, Plant and Equipment

Property and equipment consisted of the following at December 31, 2015 and 2014:

	December 31,
	2015		2014

Laboratory equipment	$	3,734,044	$	2,304,615
Office furniture and equipment		701,557		691,032
Computers		1,563,177		1,169,910
Leasehold improvements		659,949		245,558
		6,658,727		4,411,115
Less accumulated depreciation		(5,584,017)		(3,823,159)
Property and equipment, net	$	1,074,710	$	587,956

Business Combination (Tables)

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Schedule of preliminary allocation of the purchase price

The following represents the preliminary allocation of the purchase price:

Total purchase price - fair value of common stock issued	$	2,584,090

Fair value of tangible assets acquired:
Cash	$	1,367,211
Receivables		536,406
Inventory		881,273
Property and equipment		245,479
Other assets		359,587
Fair value of identifable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		637,528

Deferred tax liabilities, net		129,095
Fair value of liabilities assumed		3,327,299
	$	2,584,090

Schedule Of Provisional Estimated Fair Values

During the fourth quarter of 2015, as a result of obtaining new information about facts and circumstances that existed as of the acquisition date, the Company adjusted the provisional estimated fair values, as follows:

	As
	previously				Adjusted
	reported (1)		Adjustment		amount
Accounts receivable	$	557,112	$	(20,706)	$	536,406
Inventory		1,073,855		(192,582)		881,273
Property and equipment		250,636		(5,157)		245,479
Liabilities		3,329,058		(1,759)		3,327,299
Deferred tax liabilities		-		129,095		129,095
Goodwill		291,747		345,781		637,528
Provision (benefit) for income taxes		1,662		(130,757)		(129,095)

(1) As reported on Form 10-Q for the quarter ended September 30, 2015

Schedule of unaudited pro forma financial information

The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

Unaudited pro forma results	Year Ended December 31,
	2015		2014

Revenues	$	5,231,844	$	8,904,244
Net loss	$	(20,751,552)	$	(14,520,497)
Net loss per share	$	(2.52)	$	(6.87)

Redeemable Convertible Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2015

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Schedule of changes in the Series A Preferred Stock

The following table presents the changes in the Series A Preferred Stock during 2014 and 2015:

	Shares		Amount
Balance at December 31, 2013		1,999,864	$	1,999,864

February 2014 Issuance		1,405,096		1,361,469
April 2014 Issuance		594,904		576,433
2014 Accretion		-		627,133

Balance at December 31, 2014		3,999,864		4,564,899

2015 Accretion		-		243,762
2015 Conversions		(3,999,864)		(4,808,661)

Balance at December 31, 2015		-	$	-

Debt (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Schedule of debt outstanding

As of December 31, 2015 and 2014, the Company has a total debt outstanding as follows:

	December 31,
	2015		2014

Convertible notes	$	-	$	1,500,000
Demand promissory notes		-		1,500,000
Long term promissory notes		1,000,000		5,000
	$	1,000,000	$	3,005,000

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Note [Abstract]

Schedule of allocation of share-based compensation expense

The allocation of share-based compensation expense by operating expenses is as follows:

	Year Ended December 31,
	2015		2014

Research and development	$	240,739	$	5,234
General and administrative		619,899		55,802
Sales and marketing		584,450		3,376
	$	1,445,088	$	64,412

Schedule of share-based compensation, options granted

A summary of the status of options granted under the plan is presented below as of and for the years ended December 31, 2015 and 2014:

					Weighted-
			Weighted-		Average
			Average		Remaining		Aggregate
	Number of		Exercise		Contractual		Intrinsic
	Options		Price		Life (in years)		Value

Outstanding at January 1, 2014		20,956				8.1	$	-
Granted		401,053	$	0.05
Exercised		(1)	$	7.91			$	-
Forfeited		(17,736)	$	40.34
Outstanding at December 31, 2014		404,272	$	1.13		9.3	$	-

Granted		1,961,637	$	2.68
Exercised		(11,472)	$	0.20			$	19,519
Forfeited		(193,657)	$	0.55
Outstanding at December 31, 2015		2,160,780	$	2.60		9.1	$	1,575,646
Exercisable at December 31, 2015		432,340	$	1.36		8.6	$	632,052
Vested and expected to vest		2,138,606	$	2.60		9.1	$	1,555,185

Schedule of share-based payment award, Stock Options granted, fair value

The fair value of each option grant was estimated at the date of grant using the Black -Scholes option pricing model based on the assumptions below:

	Year Ended December 31,
	2015			2014

Annual dividend		-			-
Expected life (in years)		5.5-6.25			6.25
Risk free interest rate		1.46-1.9	%		1.84-2.02	%
Expected volatility		47.7-65.0	%		60.0	%

Schedule of warrants to purchase shares of common stock

the following warrants to purchase shares of common stock were outstanding:

						Outstanding at December 31,
		Exercise
Issuance		Price		Expiration		2015		2014
	August 2007	$	7.91		August 2017		8,921		8,921
	March 2008	$	790.54		March 2018		46		46
	November 2009	$	7.91		November 2019		6,674		6,674
	January 2010	$	7.91		January 2020		6,674		6,674
	March 2010	$	7.91		March 2020		1,277		1,277
	November 2011	$	7.91		November 2021		5,213		5,213
	December 2011	$	7.91		December 2021		664		664
	March 2012	$	109.90		March 2019		4,125		4,125
	February 2015	$	6.60		February 2025		225,011		-
	May 2015	$	6.60		May 2020		3,457,750		-
							3,716,355		33,594

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities

The Company’s deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows:

	December 31,
	2015		2014
Deferred tax assets:
NOL carryforward	$	38,797,762	$	28,704,237
R&E credit carryforward		1,994,478		1,894,478
Share-based compensation		383,153		144,742
Inventory reserve		226,299		334,578
Depreciation		313,714		246,233
Accruals and other		495,640		185,702
Total deferred tax assets		42,211,046		31,509,970
Valuation allowance		(41,554,045)		(31,505,287)

Deferred tax liabilities:
Intangible assets		(657,001)		-
Fixed assets		-		(4,683)

Net deferred tax liability	$	-	$	-

Expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit)

	2015			2014
Federal income tax benefit at statutory rates		35.0	%		34.0	%
State income tax benefit, net of Federal benefit		3.3	%		3.6	%
Change in valuation allowance		(33.1)	%		(51.1)	%
Change in state tax rates and other		(4.5)	%		13.5	%
		0.7	%		0.0	%

Commitments (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments For Capital Leases

Following is a schedule by year of the estimated future minimum payments under all operating and capital leases as of December 31, 2015:

	Capital		Operating
Year ending December 31,	Leases		Leases		Total

2016	$	294,141	$	870,484	$	1,164,625
2017		204,354		633,480		837,834
2018		109,272		568,410		677,682
2019		21,266		-		21,266
2020 and thereafter		19,494		-		19,494
Total	$	648,527	$	2,072,374	$	2,720,901
Less: amount representing interest		(70,255)
Net present value of future minimum lease payments	$	578,272
Current maturities		(251,800)
Long-term maturities	$	326,472

Schedule of Capital Leased Assets

Assets under capital leases were included in the following balance sheet categories as of December 31:

	2015		2014
Laboratory equipment	$	803,500	$	364,471
Office furniture		89,140		-
Computers		153,693		153,693
Less accumulated amortization		(402,066)		(245,030)
Capital lease assets, net	$	644,267	$	273,134

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Schedule of fair value, liabilities measured on recurring basis

The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2015:

	Balance at								Balance at
	December		Established		Change in		Reclassified		December
Description	31, 2014		in 2015		Fair Value		to Equity		31, 2015

Derivative warrant liability	$	-	$	72,333	$	647,342	$	(719,675)	$	-

Going Concern and Management's Plans (Details Textual) - USD ($)			1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Jul. 14, 2015	May 08, 2015	Jul. 31, 2015	May 31, 2015	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Conversion of Stock [Line Items]
Proceeds from Convertible Debt								$ 1,388,815	$ 1,472,386
Proceeds from Notes Payable								$ 1,741,667	1,488,229
Units Of Stock And Warrants Issued During Period Shares Initial Public Offering		2,850,000
Stock And Warrants Issued During Period Shares Initial Public Offering Purchase Price Per Unit		$ 6.00
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Debt Conversion, Original Debt, Amount		2,100,000
Conversion of Stock, Shares Issued								7,374,852
Proceeds from Issuance Initial Public Offering		$ 17,100,000
Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			1,136,364
Common Stock
Conversion of Stock [Line Items]
Stock Issued During Period, Shares, New Issues								2,500,000
Warrants Issued During Period On Exercise Of Over Allotment Option Shares		422,500
Shares Issued, Price Per Share		$ 6.00
Common Stock \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Proceeds From Issuance Of Shares And Debt	$ 6,000,000
Stock Issued During Period, Shares, New Issues	1,136,364
Shares Issued, Price Per Share	$ 4.40
Initial public offering
Conversion of Stock [Line Items]
Debt Conversion, Converted Instrument, Amount								$ 2,100,000	$ 0
Debt Conversion, Converted Instrument, Shares Issued		350,000						1,875,000
Proceeds from Issuance Initial Public Offering		$ 12,100,000
Initial public offering \| Common Stock
Conversion of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued				350,000
Convertible Notes Payable
Conversion of Stock [Line Items]
Proceeds from Convertible Debt								$ 1,500,000
Short-term Demand Notes
Conversion of Stock [Line Items]
Proceeds from Notes Payable							$ 2,300,000	800,000
Repayments of Notes Payable					$ 200,000
Debt Conversion, Converted Instrument, Amount						$ 300,000
Promissory Note \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Debt Instrument, Face Amount	$ 1,000,000
Promissory Note \| Common Stock \| Merck Global Health Innovation Fund LLC
Conversion of Stock [Line Items]
Proceeds From Issuance Of Common Stock And Notes Payable								$ 6,000,000

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventories
Raw materials and supplies	$ 362,526	$ 40,749
Work-in process	150,369	135,625
Finished goods	313,117	193,368
Total inventory	$ 826,012	$ 369,742

Summary of Significant Accounting Policies (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Cost	$ 2,013,000
Accumulated Amortization	(124,186)
Net balance at December 31, 2015	1,888,814	$ 0
Trademarks and tradenames
Significant Accounting Policies [Line Items]
Cost	461,000
Accumulated Amortization	(21,471)
Net balance at December 31, 2015	439,529
Developed technology
Significant Accounting Policies [Line Items]
Cost	458,000
Accumulated Amortization	(30,474)
Net balance at December 31, 2015	427,526
Customer relationships
Significant Accounting Policies [Line Items]
Cost	1,094,000
Accumulated Amortization	(72,241)
Net balance at December 31, 2015	$ 1,021,759

Summary of Significant Accounting Policies (Details 2) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Property and equipment, Gross	$ 6,658,727	$ 4,411,115
Less accumulated depreciation	(5,584,017)	(3,823,159)
Property and equipment, net	1,074,710	587,956
Laboratory equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross	3,734,044	2,304,615
Office furniture and equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross	701,557	691,032
Computer equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross	1,563,177	1,169,910
Leasehold improvements [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross	$ 659,949	$ 245,558

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	May 08, 2015
Significant Accounting Policies [Line Items]
Allowance for Doubtful Accounts Receivable	$ 15,596	$ 79,697
Inventory Valuation Reserves	591,051	867,816
Operating Loss Carryforwards	$ 90,297,000	$ 76,268,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,000,000	5,900,000
Cash, FDIC Insured Amount	$ 250,000
Income Tax Expense (Benefit)	(129,095)	$ 0
Goodwill	637,528	0
Letters of Credit Outstanding, Amount	243,380
Amortization of Intangible Assets	124,186	57,594
Depreciation, Total	500,467	516,324
Selling and Marketing Expense	4,305,444	2,058,085
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	268,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	268,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	268,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	268,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 268,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Equipment [Member]
Significant Accounting Policies [Line Items]
Selling and Marketing Expense	$ 175,000	$ 101,000
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Trademarks [Member]
Significant Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Common Stock [Member]
Significant Accounting Policies [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	7,374,852		7,374,852
Series A Convertible Redeemable Preferred Stock
Significant Accounting Policies [Line Items]
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required	70.00%
Temporary Equity, Shares Outstanding	0	3,999,864
Accounts Receivable \| Customer One
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	25.00%	79.00%
Accounts Receivable \| Customer Two
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		15.00%
Sales Revenue, Net [Member] \| Hitachi High - Technologies Corporation
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	11.00%	64.00%
Maximum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due	60 days
Fair Value Assumptions, Expected Term	10 years
Minimum
Significant Accounting Policies [Line Items]
Accounts Receivable Period Due	30 days
Fair Value Assumptions, Expected Term	6 years 3 months

Business Combination (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Fair value of identifiable intangible assets acquired:
Fair value of goodwill	$ 637,528	$ 0
AdvanDx [Member]
Business Acquisition [Line Items]
Total purchase price - fair value of common stock issued	2,584,090
Fair value of tangible assets acquired:
Cash	1,367,211
Receivables	536,406
Inventory	881,273
Property and equipment	245,479
Other assets	359,587
Fair value of identifiable intangible assets acquired:
Customer relationships	1,094,000
Developed technology	458,000
Trademarks and tradenames	461,000
Fair value of goodwill	637,528
Deferred tax liabilities, net	129,095
Fair value of liabilities assumed	3,327,299
Total acquisition purchase price Allocation	$ 2,584,090

Business Combination (Details 1) - USD ($)

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Goodwill

$ 637,528

$ 0

Provision (benefit) for income taxes

(129,095)

$ 0

AdvanDx [Member]

Accounts receivable

536,406

Inventory

881,273

Property and equipment

245,479

Liabilities

3,327,299

Deferred tax liabilities

129,095

Goodwill

637,528

Provision (benefit) for income taxes

(129,095)

Scenario, Previously Reported [Member]

Accounts receivable

^[1]

557,112

Inventory

^[1]

1,073,855

Property and equipment

^[1]

250,636

Liabilities

^[1]

3,329,058

Deferred tax liabilities

^[1]

Goodwill

^[1]

291,747

Provision (benefit) for income taxes

^[1]

1,662

Scenario, Adjustment [Member]

Accounts receivable

(20,706)

Inventory

(192,582)

Property and equipment

(5,157)

Liabilities

(1,759)

Deferred tax liabilities

129,095

Goodwill

345,781

Provision (benefit) for income taxes

$ (130,757)

[1]	As reported on Form 10-Q for the quarter ended September 30, 2015

Business Combination (Details 2) - USD ($)	12 Months Ended
Business Combination (Details 2) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition, Pro Forma Information
Revenues	$ 5,231,844	$ 8,904,244
Net loss	$ (20,751,552)	$ (14,520,497)
Net loss per share	$ (2.52)	$ (6.87)

Business Combination (Details Textual) - USD ($)		12 Months Ended
Business Combination (Details Textual) - USD ($)	Jul. 14, 2015	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 637,528	$ 0
Payments of Merger Related Costs, Financing Activities		500,000
Deferred Tax Assets, Tax Credit Carryforwards, Foreign			4,300,000
Deferred Tax Liabilities, Net, Total			$ 100,000
AdvanDx [Member]
Business Acquisition [Line Items]
Goodwill		637,528
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized		1,700,000
Net Income Loss Generated by Acquired Entity Post Acquisition Date		$ (2,100,000)
AdvanDx [Member] \| Equity Issued in Business Combination [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	681,818
Equity Issued in Business Combination, Fair Value Disclosure	$ 2,600,000

Merck GHI Financing (Details Textual) - USD ($)		12 Months Ended
Merck GHI Financing (Details Textual) - USD ($)	Jul. 14, 2015	Dec. 31, 2015	Dec. 31, 2014	Jul. 31, 2015
Common Stock and Note Purchase Agreement [Line Items]
Proceeds from Issuance of Common Stock		$ 17,366,620	$ 0
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 58,566
Merck GHI Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Stock Issued During Period, Shares, New Issues	1,136,364
Shares Issued, Price Per Share	$ 4.40
Proceeds from Issuance of Common Stock	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%			8.00%
Debt Instrument, Face Amount	$ 1,000,000
Fees Related to Common Stock and Debt Transaction	50,000
Payments of Debt Issuance Costs	8,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 42,000

Redeemable Convertible Preferred Stock (Details) - USD ($)	1 Months Ended		12 Months Ended
	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Conversions			$ (7,804,172)
Series A Preferred Stock [Member]
Balance (in shares)			3,999,864	1,999,864
Balance			$ 4,564,899	$ 1,999,864
Issuance (In shares)	594,904	1,405,096			1,999,864
Issuance	$ 576,433	$ 1,361,469
Accretion			$ 243,762	$ 627,133
Conversions (In shares)			(3,999,864)
Conversions			$ (4,808,661)
Balance (In shares)			0	3,999,864
Balance			$ 0	$ 4,564,899

Redeemable Convertible Preferred Stock (Details Textual) - USD ($)		1 Months Ended			12 Months Ended
	May 08, 2015	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Debt Conversion, Original Debt, Amount	$ 2,100,000
Conversion of Stock, Shares Issued					7,374,852
Series A Preferred Stock
Class of Stock [Line Items]
Temporary Equity, Shares Issued		594,904	1,405,096	1,999,864
Temporary Equity, Par or Stated Value Per Share				$ 1.00
Debt Conversion, Original Debt, Amount				$ 1,999,864
Proceeds from Issuance of Convertible Preferred Stock		$ 594,904	$ 1,405,096
Temporary Equity, Shares Outstanding				1,999,864	0	3,999,864
Temporary Equity Shares Outstanding Convertible Into Common Stock Number						3,999,864
Preferred Stock, Dividend Rate, Percentage					8.00%
Temporary Equity Redemption Request Of Minimum Percentage Of Holders Of Outstanding Preferred Stock Required					70.00%
Payment of Financing and Stock Issuance Costs, Total						$ 62,098

Debt (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt, Long-term and Short-term, Combined Amount, Total	$ 1,000,000	$ 3,005,000
Convertible notes
Debt Instrument [Line Items]
Convertible notes	0	1,500,000
Demand promissory notes
Debt Instrument [Line Items]
Short-term Debt	0	1,500,000
Long term promissory notes
Debt Instrument [Line Items]
Long-term Debt	$ 1,000,000	$ 5,000

Debt (Details Textual)		1 Months Ended			2 Months Ended	3 Months Ended			6 Months Ended	12 Months Ended
Debt (Details Textual)	May 08, 2015 USD ($) shares	Jul. 31, 2015 USD ($)	May 31, 2015 USD ($) shares	Jun. 30, 2013 USD ($)	Mar. 31, 2015 USD ($) $ / shares	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($) $ / shares	Sep. 30, 2014 USD ($)	Mar. 31, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($)	Jul. 14, 2015 USD ($)	Dec. 31, 2009 USD ($)
Debt Instrument [Line Items]
Proceeds from Notes Payable										$ 1,741,667	$ 1,488,229
Proceeds from Convertible Debt										1,388,815	1,472,386
Interest Expense, Debt			$ 1,500,000							1,800,000	100,000
Amortization of Financing Costs										71,421
Repayments of Debt										155,000	5,000
Merck GHI Financing Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%										8.00%
Proceeds from Other Short-term Debt		$ 1,000,000
Debt Instrument, Face Amount												$ 1,000,000
Repayments of Debt						$ 150,000
Department of Business and Economic Development Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 100,000
Repayments of Debt				75,000
Interest Payable				$ 11,811
Loan From Department Of Business And Economic Development, Maryland [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													3.00%
Debt Instrument, Face Amount													$ 100,000
Loan From Department Of Business And Economic Development, Montgomery County [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 10,000
IPO [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount										$ 2,100,000	0
Debt Conversion, Converted Instrument, Shares Issued \| shares	350,000									1,875,000
Interest Expense, Debt											$ 1,500,000
Common Stock Percent										110.00%
IPO [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued \| shares			350,000
2014 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Proceeds from Convertible Debt								$ 1,500,000
2015 Convertible Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					8.00%	0.00%	8.00%		8.00%
Proceeds from Other Short-term Debt					$ 1,500,000
Fair Value Adjustment of Warrants	$ 700,000
2015 Convertible Notes \| Common Stock [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares										225,011
Debt Instrument, Convertible, Conversion Price \| $ / shares					$ 1.00		$ 1.00		$ 1.00
2015 Convertible Notes \| Pre IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio					1.25
2015 Convertible Notes \| Post IPO
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio					1.00
Short-term Demand Notes
Debt Instrument [Line Items]
Proceeds from Notes Payable									$ 2,300,000	$ 800,000
Debt Conversion, Converted Instrument, Amount							$ 300,000
Debt Instrument, Interest Rate, Stated Percentage										8.00%

Stockholders' Equity (Details) - USD ($)	12 Months Ended
Stockholders' Equity (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 1,445,088	$ 64,412
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	240,739	5,234
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	619,899	55,802
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 584,450	$ 3,376

Stockholders' Equity (Details 1) - USD ($)	12 Months Ended
Stockholders' Equity (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding Balance	404,272	20,956
Number of Options, Granted	1,961,637	401,053
Number of Options, Exercised	(11,472)	(1)
Number of Options, Forfeited	(193,657)	(17,736)
Number of Options, Outstanding Balance	2,160,780	404,272	20,956
Number of Options, Exercisable	432,340
Number of Options, Vested and expected to vest	2,138,606
Weighted Average Exercise Price, Outstanding Balance	$ 1.13
Weighted Average Exercise Price, Granted	2.68	0.05
Weighted Average Exercise Price, Exercised	0.20	7.91
Weighted Average Exercise Price, Forfeited	0.55	40.34
Weighted Average Exercise Price, Outstanding Balance	2.60	$ 1.13
Weighted Average Exercise Price, Exercisable	1.36
Weighted Average Exercise Price, Vested and expected to vest	$ 2.60
Weighted-Average Remaining Contractual Life, Outstanding (in years)	9 years 1 month 6 days	9 years 3 months 18 days	8 years 1 month 6 days
Weighted-Average Remaining Contractual Life, Exercisable (in years)	8 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest (in years)	9 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Exercised	19,519	0
Aggregate Intrinsic Value, Outstanding	1,575,646	$ 0	$ 0
Aggregate Intrinsic Value, Exercisable	632,052
Aggregate Intrinsic Value, Vested and expected to vest	$ 1,555,185

Stockholders' Equity (Details 2)	12 Months Ended
Stockholders' Equity (Details 2)	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual dividend	0.00%	0.00%
Expected life (in years)		6 years 3 months
Risk free interest rate, minimum	1.46%	1.84%
Risk free interest rate, maximum	1.90%	2.02%
Expected volatility, minimum	47.70%
Expected volatility, maximum	65.00%
Expected volatility		60.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years 3 months

Stockholders' Equity (Details 3) - $ / shares	12 Months Ended
Stockholders' Equity (Details 3) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding	3,716,355	33,594
August 2007
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2017-08
Outstanding	8,921	8,921
March 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 790.54
Expiration	2018-03
Outstanding	46	46
November 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2019-11
Outstanding	6,674	6,674
January 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2020-01
Outstanding	6,674	6,674
March 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2020-03
Outstanding	1,277	1,277
November 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2021-11
Outstanding	5,213	5,213
December 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91
Expiration	2021-12
Outstanding	664	664
March 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 109.90
Expiration	2019-03
Outstanding	4,125	4,125
February 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60
Expiration	2025-02
Outstanding	225,011	0
May 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60
Expiration	2020-05
Outstanding	3,457,750	0

Stockholders' Equity (Details Textual) - USD ($)			1 Months Ended			3 Months Ended	12 Months Ended
Stockholders' Equity (Details Textual) - USD ($)	Jul. 14, 2015	May 08, 2015	Jul. 31, 2015	May 31, 2015	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Oct. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense							$ 1,445,088	$ 64,412
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							1,961,637	401,053
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 2.68	$ 0.05
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							$ 58,566
Proceeds from Issuance of Warrants		$ 4,225
Proceeds From Issuance Of Units Under Initial Public Offering Gross		17,100,000
Proceeds From Issuance Of Units Under Initial Public Offering Net		$ 12,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value							$ 1,140,079	$ 47,331
Common Stock, Shares Authorized						200,000,000	200,000,000	200,000,000
Common Stock, Shares, Issued						12,547,684	12,547,684	493,178
Preferred Stock, Shares Authorized						10,000,000	10,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total						$ 3,400,000	$ 3,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							1 year 6 months 25 days
Common Stock, Shares, Outstanding						12,547,684	12,547,684	493,178
Proceeds from Issuance of Common Stock							$ 17,366,620	$ 0
Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues			1,136,364
Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		3,272,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 6.60
Expiration Date of Warrants Issued		May 08, 2020
IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Amount							$ 2,100,000	$ 0
Debt Conversion, Converted Instrument, Shares Issued		350,000					1,875,000
Demand Notes Payable [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Amount		$ 2,100,000
2002 plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									825,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,355,000	1,355,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						233,562	233,562
Share-based Compensation Arrangement by Share-based Payment Award, Common stock Percentage							4.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value							$ 2.80	$ 0.03
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					130,640	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 1.70
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues							2,500,000
Stock and Warrants Issued in Conjunction with Initial Public Offering		2,850,000
Offering Price Per Unit		$ 6.00
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 2,900,000
Warrants Issued During Period On Exercise Of Over Allotment Option Shares		422,500
Convertible Preferred Stock, Shares Issued upon Conversion		7,374,852				7,374,852	7,374,852
Shares Of Stock Issued For Restricted Stock Unit Exercises								130,640
Common Stock [Member] \| Merck Global Health Innovation Fund LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues	1,136,364
Offering Price Per Unit	$ 4.40
Proceeds from Issuance of Common Stock	$ 5,000,000
Common Stock [Member] \| Over-Allotment Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		185,250
Common Stock [Member] \| IPO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Conversion, Converted Instrument, Shares Issued				350,000

Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
NOL carryforward	$ 38,797,762	$ 28,704,237
R&E credit carryforward	1,994,478	1,894,478
Share-based compensation	383,153	144,742
Inventory reserve	226,299	334,578
Depreciation	313,714	246,233
Accruals and other	495,640	185,702
Total deferred tax assets	42,211,046	31,509,970
Valuation allowance	(41,554,045)	(31,505,287)
Deferred tax liabilities:
Intangible assets	(657,001)	0
Fixed assets	0	(4,683)
Net deferred tax liability	$ 0	$ 0

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2015	Dec. 31, 2014
Income Tax [Line Items]
Federal income tax benefit at statutory rates	35.00%	34.00%
State income tax benefit, net of Federal benefit	3.30%	3.60%
Change in valuation allowance	(33.10%)	(51.10%)
Change in state tax rates and other	(4.50%)	13.50%
Total	0.70%	0.00%

Income Taxes (Details Textual) - USD ($)	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Income Tax [Line Items]
Deferred Tax Assets, Net of Valuation Allowance, Total	$ 41,554,045	$ 31,505,287
Deferred Tax Assets, Valuation Allowance	41,554,045	31,505,287
Operating Loss Carryforwards	90,297,000	76,268,000
Domestic Tax Authority [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 90,297,225	$ 76,267,809
Operating Loss Carry forwards, Expiration Terms	begin to expire in 2022.

Commitments (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Capital Leases
2016	$ 294,141
2017	204,354
2018	109,272
2019	21,266
2020 and thereafter	19,494
Total	648,527
Less: amount representing interest	(70,255)
Net present value of future minimum lease payments	578,272
Current maturities	251,800	$ 100,499
Long-term maturities	377,908	$ 134,149
Operating Leases
2016	870,484
2017	633,480
2018	568,410
2019	0
2020 and thereafter	0
Total	2,072,374
Total
2016	1,164,625
2017	837,834
2018	677,682
2019	21,266
2020 and thereafter	19,494
Total	$ 2,720,901

Commitments (Details 1) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Less accumulated amortization	$ (402,066)	$ (245,030)
Capital lease assets, net	644,267	273,134
Laboratory Equipment [Member]
Loss Contingencies [Line Items]
Capital Leased Assets Gross	803,500	364,471
Office Furniture [Member]
Loss Contingencies [Line Items]
Capital Leased Assets Gross	89,140	0
Computer [Member]
Loss Contingencies [Line Items]
Capital Leased Assets Gross	$ 153,693	$ 153,693

Commitments (Details Textual) - USD ($)	12 Months Ended
Commitments (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Loss Contingencies [Line Items]
Operating Leases, Rent Expense, Net, Total	$ 1,027,174	$ 883,155
Capital Lease Obligations [Member]
Loss Contingencies [Line Items]
Capital Leases, Income Statement, Amortization Expense	$ 157,036	$ 122,411

License Agreements, Research Collaborations and Development Agreements (Details Textual)	1 Months Ended	12 Months Ended
	Sep. 30, 2013 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Future Minimum Royalty Payments Due		$ 270,000
License Upfront Payment Received	$ 250,000
Royalty (Income) Expense		205,147	$ 97,134
Licenses Revenue		$ 336,102	$ 2,411,120
Number Of License Agreements		3

Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 370,539	$ 138,339
Payments to Acquire Equipment on Lease	$ 119,919	$ 59,412

Fair Value Measurements (Details) - Warrant	12 Months Ended
Fair Value Measurements (Details) - Warrant	Dec. 31, 2015 USD ($)
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the begining of the period	$ 0
Established in 2015	72,333
Change in Fair Value	647,342
Reclassified to Equity	(719,675)
Balance at the end of the period	$ 0